The IFN-γ-sEV vaccine, using PCa-sEVs, enhanced M1 macrophage activity and antibody production, leading to clearance of PCa-sEVs, reduction in Treg levels, suppression of tumor-promoting expressions, and ultimately, inhibition of tumor growth and improved survival in mice with PCa [145]. This evidence concerns the gene IFNG and neoplasm.